Ling Ling Huang

This inventor holds 63 USPTO granted patents and 27 published patent applications, plus 15 CIPO patents and 22 EPO patents, primarily in Antibody Engineering (CPC class C07K). Top assignees: Macrogenics, Inc., Hofstra University, Other. Active years: 1977-2024.

USPTO Granted Patents = 63 (Patent Applications = 27)

% Patents Active = 77.8

CIPO Patents = 15 (Patent Applications = 7)

EPO Patents = 22 (Patent Applications = 21)

Average Co-Inventor Count = 3.0

ph-index = 18

Forward Citations = 1,208(Granted Patents)

Forward Citations (Not Self Cited) = 875(Dec 10, 2025)

Inventors with similar research interests:

Location History:

San Jose, CA (US) (1977)
Gaithersburg, MD (US) (2006 - 2015)
Westbury, NY (US) (2021)
Rockville, MD (US) (2023)
Bethesda, MD (US) (2009 - 2024)

Company Filing History:

2 out of 834,411

Other

patents

Years Active: 1977-2024

Loading Chart...

Areas of Expertise:

CD3-Binding Molecules

HER2/neu-Specific Antibodies

Bi-Specific Diabodies

B7-H3 Directed Antibodies

Covalent Diabodies

Multi-Chain Polypeptides

Antibody Drug Conjugates

Immunologically Active Fragments

Nuclear Magnetic Resonance

Binding Domains

Combination Therapies

63 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12049501 - CD3-binding molecules capable of binding to human and non-human CD3 (2024-07-30),

2. 12024569 - HER2/neu-specific antibodies and methods of using same (2024-07-02),

3. 11820818 - Multi-chain polypeptide-containing tri-specific binding molecules (2023-11-21),

4. 11685781 - Variant CD3-binding domains and their use in combination therapies for the treatment of disease (2023-06-27),

5. 11591400 - B7-H3 directed antibody drug conjugates (2023-02-28),

6. 11384149 - Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof (2022-07-12),

7. 11254748 - Covalent diabodies and uses thereof (2022-02-22),

8. 11254747 - Covalent diabodies and uses thereof (2022-02-22),

9. 11111299 - CD3-binding molecules capable of binding to human and non-human CD3 (2021-09-07),

10. 11098125 - FcγRIIB-specific antibodies and methods of use thereof (2021-08-24),

11. 11085891 - Nuclear magnetic resonance implemented synthetic indole and indazole cannabinoid detection, identification, and quantification (2021-08-10),

12. 11028183 - HER2/neu-specific antibodies and methods of using same (2021-06-08),

13. 10961311 - B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof (2021-03-30),

14. 10787521 - Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof (2020-09-29),

15. 10730945 - Antibodies reactive with B7-H3 and users thereof (2020-08-04),

Title: Innovations of Ling Ling Huang: A Leader in Biopharmaceutical Patents

Introduction: Ling Ling Huang is an accomplished inventor based in San Jose, CA, known for his substantial contributions to the field of biopharmaceuticals. With 62 patents to his name, Huang has made significant strides in developing novel therapeutic approaches, particularly in cancer treatment and autoimmune diseases.

Latest Patents: Among Huang's most recent inventions are two groundbreaking patents. The first patent focuses on CD3-binding molecules capable of binding to both human and non-human CD3. This innovation is particularly notable for its cross-reactivity with CD3 of non-human mammals, such as cynomolgus monkeys, and offers promising applications in treating cancer, autoimmune disorders, and inflammatory diseases. The second patent pertains to HER2/neu-specific antibodies, particularly chimeric 4D5 antibodies that have reduced glycosylation compared to existing 4D5 antibodies. This invention also details methods for utilizing these antibodies in the diagnosis and treatment of various diseases, including cancers and autoimmune disorders.

Career Highlights: Ling Ling Huang has played a pivotal role in advancing therapeutic biologics during his career. His extensive experience in the biopharmaceutical sector has allowed him to innovate and improve treatment options for complex diseases. His contributions have cemented his reputation as a leading inventor in the field.

Collaborations: Huang has collaborated with notable professionals in the biopharmaceutical industry. Two of his coworkers, Leslie Sydnor Johnson and Ezio Bonvini, have contributed to his research efforts and innovations. Such collaborations enhance the development of his inventive concepts and accelerate advancements in therapeutic treatments.

Conclusion: With a remarkable portfolio of 62 patents, Ling Ling Huang stands out as a significant innovator in biopharmaceuticals. His inventions, particularly focused on treatment methodologies for complex diseases, continue to influence the healthcare landscape. His collaborative efforts highlight the importance of teamwork in fostering innovation and advancing therapeutic solutions.